A federal judge on Sept. 24 ruled that a Cincinnati, Ohio-area healthcare provider could require employees to get vaccinated against Covid-19 or risk losing their job, in what appears to be the first ruling of its kind for a private employer in the United States.
Amarin announced a new marketing strategy for the company’s Vascepa drug in the United States, starting with reducing the Irish-American biopharmaceutical firm’s sales rep numbers by more than 50 percent.
As the fraud trial of Theranos founder Elizabeth Holmes headlines the pharma legal news, other court-related cases are taking place, including a ruling in the legal spat between Takeda and AbbVie over a supply agreement for the prostate cancer drug Lupron.
CanSino Biologics Inc.’s single-dose Covid-19 vaccine – given at a lower dosage than that for adults – is safe and triggers an immune response in children aged 6-17, results from a small trial showed.
Cassava Sciences announced top-line results Sept. 22 from a 12-month interim analysis of the company’s Alzheimer’s drug candidate simufilam.
Med Ad News spoke with Mike Myers (managing director and partner of CrowdPharm and managing director and founder of Cross & Wild) and Steve Bernstein (CEO of Bernstein-Rein Advertising and CrowdPharm partner) about the combination of CrowdPharm and Cross & Wild, what makes CrowdPharm different from other agencies, and how they plan to expand the business in the future.
Matthew Howes was appointed Chief Strategy Officer at The Greater Than One Group (GTO), a privately held, global marketing and communications agency with a proprietary model and focused approach leveraging data, content and media.
Fishawack Health, a leading commercialization partner for the life science industry, appointed Elizabeth (Liz) Landon to a newly created executive role as Chief People Officer.
Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.
With $19 million in seed funding led by the Retinal Degeneration Fund, Opus Genetics launched with a mission to develop gene therapies for rare forms of blindness driven by genetic mutations.